Tisotumab vedotin is a type of targeted therapy called an antibody-drug conjugate. It is made of a monoclonal antibody chemically linked to a cancer-killing drug. The monoclonal antibody binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and kills them. Tisotumab vedotin may also stimulate the immune system to kill cancer cells.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Tisotumab vedotin-tftv is approved to treat:
- Cervical cancer that is recurrent or metastatic. It is used in women whose cancer got worse during or after treatment with chemotherapy.
Tisotumab vedotin-tftv is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.
Tisotumab vedotin-tftv is also being studied in the treatment of other types of cancer.
More About Tisotumab Vedotin-tftv
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Tisotumab Vedotin-tftv - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Tisotumab Vedotin-tftv - Check for trials from NCI's list of cancer clinical trials now accepting patients.